trial
as of 2026-07-01A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
NCTId NCT01412060
at a glance
Phase 3 · Completed
Enrollment 765 (actual)
Sponsored by Forest Laboratories
Primary completion 2014-09-03
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
765 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-09-27
Primary completion
2014-09-03
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Indications
Sponsors
Forest LaboratoriesLead Sponsor
Gedeon Richter Ltd.Collaborator
Investigators
1
Willie EarleyStudy Director
Sites
73 total
Little Rock, United StatesCerritos, United StatesCosta Mesa, United StatesCulver City, United StatesLong Beach, United StatesOceanside, United StatesOrange, United StatesParamount, United StatesSan Diego, United StatesWashington D.C., United StatesLeesburg, United StatesAtlanta, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
765
Phase
PHASE3
Primary Completion Date
2014-09-03
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
collaborator
company
indication
indication
indication
investigator
person